Cargando…
Adults with early-onset type 2 diabetes (aged 18–39 years) are severely underrepresented in diabetes clinical research trials
AIMS/HYPOTHESIS: Early-onset adult type 2 diabetes (diagnosed between ages 18 and 39 years) is increasingly prevalent and associated with poor long-term outcomes. We hypothesised that individuals with early-onset adult type 2 diabetes were underrepresented in the prominent research trials that under...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351852/ https://www.ncbi.nlm.nih.gov/pubmed/32483683 http://dx.doi.org/10.1007/s00125-020-05174-9 |
_version_ | 1783557528851841024 |
---|---|
author | Sargeant, Jack A. Brady, Emer M. Zaccardi, Francesco Tippins, Frances Webb, David R. Aroda, Vanita R. Gregg, Edward W. Khunti, Kamlesh Davies, Melanie J. |
author_facet | Sargeant, Jack A. Brady, Emer M. Zaccardi, Francesco Tippins, Frances Webb, David R. Aroda, Vanita R. Gregg, Edward W. Khunti, Kamlesh Davies, Melanie J. |
author_sort | Sargeant, Jack A. |
collection | PubMed |
description | AIMS/HYPOTHESIS: Early-onset adult type 2 diabetes (diagnosed between ages 18 and 39 years) is increasingly prevalent and associated with poor long-term outcomes. We hypothesised that individuals with early-onset adult type 2 diabetes were underrepresented in the prominent research trials that underpin type 2 diabetes management guidelines. METHODS: We reviewed the mean age of the study populations recruited to 90 prominent trials in type 2 diabetes, including 37 cardio-renal outcomes trials across a range of pharmacological, non-pharmacological and multifactorial interventions, 28 trials from the phase III programmes of three representative glucose-lowering therapies used routinely in clinical practice (empagliflozin, liraglutide and sitagliptin) and 25 prominent trials of diabetes self-management education and support or intensive lifestyle interventions (diet or supervised exercise training). We then estimated the number of individuals within these trials who were aged between 18 and 39 years. RESULTS: Across all 90 trials, the mean age of 268,978 participants was 63 years (range 51–69 years in individual trials). In 73 trials (81%), <5% of participants were estimated to be aged 18–39 years, despite this age group representing ~15–20% of the adult type 2 diabetes population. Twenty-nine of these trials (32%; total 164,953 participants) excluded individuals below 40 years of age altogether. CONCLUSIONS/INTERPRETATION: Guidelines for early-onset adult type 2 diabetes are extrapolated predominantly from evidence in older individuals. Strategies to support the participation of individuals with early-onset adult type 2 diabetes in future research are imperative to ensure guidelines for these high-risk individuals are evidence-based. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-020-05174-9) contains peer-reviewed but unedited supplementary material, which is available to authorised users. |
format | Online Article Text |
id | pubmed-7351852 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-73518522020-07-14 Adults with early-onset type 2 diabetes (aged 18–39 years) are severely underrepresented in diabetes clinical research trials Sargeant, Jack A. Brady, Emer M. Zaccardi, Francesco Tippins, Frances Webb, David R. Aroda, Vanita R. Gregg, Edward W. Khunti, Kamlesh Davies, Melanie J. Diabetologia Short Communication AIMS/HYPOTHESIS: Early-onset adult type 2 diabetes (diagnosed between ages 18 and 39 years) is increasingly prevalent and associated with poor long-term outcomes. We hypothesised that individuals with early-onset adult type 2 diabetes were underrepresented in the prominent research trials that underpin type 2 diabetes management guidelines. METHODS: We reviewed the mean age of the study populations recruited to 90 prominent trials in type 2 diabetes, including 37 cardio-renal outcomes trials across a range of pharmacological, non-pharmacological and multifactorial interventions, 28 trials from the phase III programmes of three representative glucose-lowering therapies used routinely in clinical practice (empagliflozin, liraglutide and sitagliptin) and 25 prominent trials of diabetes self-management education and support or intensive lifestyle interventions (diet or supervised exercise training). We then estimated the number of individuals within these trials who were aged between 18 and 39 years. RESULTS: Across all 90 trials, the mean age of 268,978 participants was 63 years (range 51–69 years in individual trials). In 73 trials (81%), <5% of participants were estimated to be aged 18–39 years, despite this age group representing ~15–20% of the adult type 2 diabetes population. Twenty-nine of these trials (32%; total 164,953 participants) excluded individuals below 40 years of age altogether. CONCLUSIONS/INTERPRETATION: Guidelines for early-onset adult type 2 diabetes are extrapolated predominantly from evidence in older individuals. Strategies to support the participation of individuals with early-onset adult type 2 diabetes in future research are imperative to ensure guidelines for these high-risk individuals are evidence-based. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-020-05174-9) contains peer-reviewed but unedited supplementary material, which is available to authorised users. Springer Berlin Heidelberg 2020-06-02 2020 /pmc/articles/PMC7351852/ /pubmed/32483683 http://dx.doi.org/10.1007/s00125-020-05174-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Short Communication Sargeant, Jack A. Brady, Emer M. Zaccardi, Francesco Tippins, Frances Webb, David R. Aroda, Vanita R. Gregg, Edward W. Khunti, Kamlesh Davies, Melanie J. Adults with early-onset type 2 diabetes (aged 18–39 years) are severely underrepresented in diabetes clinical research trials |
title | Adults with early-onset type 2 diabetes (aged 18–39 years) are severely underrepresented in diabetes clinical research trials |
title_full | Adults with early-onset type 2 diabetes (aged 18–39 years) are severely underrepresented in diabetes clinical research trials |
title_fullStr | Adults with early-onset type 2 diabetes (aged 18–39 years) are severely underrepresented in diabetes clinical research trials |
title_full_unstemmed | Adults with early-onset type 2 diabetes (aged 18–39 years) are severely underrepresented in diabetes clinical research trials |
title_short | Adults with early-onset type 2 diabetes (aged 18–39 years) are severely underrepresented in diabetes clinical research trials |
title_sort | adults with early-onset type 2 diabetes (aged 18–39 years) are severely underrepresented in diabetes clinical research trials |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351852/ https://www.ncbi.nlm.nih.gov/pubmed/32483683 http://dx.doi.org/10.1007/s00125-020-05174-9 |
work_keys_str_mv | AT sargeantjacka adultswithearlyonsettype2diabetesaged1839yearsareseverelyunderrepresentedindiabetesclinicalresearchtrials AT bradyemerm adultswithearlyonsettype2diabetesaged1839yearsareseverelyunderrepresentedindiabetesclinicalresearchtrials AT zaccardifrancesco adultswithearlyonsettype2diabetesaged1839yearsareseverelyunderrepresentedindiabetesclinicalresearchtrials AT tippinsfrances adultswithearlyonsettype2diabetesaged1839yearsareseverelyunderrepresentedindiabetesclinicalresearchtrials AT webbdavidr adultswithearlyonsettype2diabetesaged1839yearsareseverelyunderrepresentedindiabetesclinicalresearchtrials AT arodavanitar adultswithearlyonsettype2diabetesaged1839yearsareseverelyunderrepresentedindiabetesclinicalresearchtrials AT greggedwardw adultswithearlyonsettype2diabetesaged1839yearsareseverelyunderrepresentedindiabetesclinicalresearchtrials AT khuntikamlesh adultswithearlyonsettype2diabetesaged1839yearsareseverelyunderrepresentedindiabetesclinicalresearchtrials AT daviesmelaniej adultswithearlyonsettype2diabetesaged1839yearsareseverelyunderrepresentedindiabetesclinicalresearchtrials |